AI-powered control towers and digital twins are emerging as essential tools to prevent costly supply chain failures and restore operational reliability.

As specialty drug spend tops 50% of pharmacy costs, health system specialty pharmacies are evolving from dispensers into longitudinal care management partners. Specialty pharmacies are moving beyond ...

Tommy Bramley explains how real-world evidence is reshaping how specialty pharma demonstrates value — from trial design to payer negotiations and patient outcomes.

Ben Sharples, LogiPharma event director, examines how life sciences organizations are adapting to AI in the supply chain, with expert testimony from LogiPharma partners.

Erez Israeli explains how Dr. Reddy's approached commercial readiness for its generic semaglutide launch in Canada and what vertical integration in peptide manufacturing means for the GLP-1 market.

Geopolitical supply chain mapping identifies hidden dependencies across corridors, ports, airports, customs gateways, and carriers that can undermine continuity despite apparent supplier ...

Wilhelm's comments describe a supply chain strategy built around flexibility, balancing inventory positioned close to ...

Medicaid work requirements under the One Big Beautiful Bill Act demand employment/volunteering documentation and clinician attestations, while exemption severity criteria vary by state and may be ...

In this week's Pharma Pulse, Cardinal Health expands its at-Home Solutions business with two acquisitions, President Trump lays out a phased tariff schedule for generic drugs, and Novo Nordisk sues ...

Rising U.S. prescription spending heightens urgency to identify when to trigger clinical review, discontinue payment, or shift to lower-cost options before avoidable spend accrues. “Subtraction ...

Amy Niles of the Patient Advocate Foundation revisits her 2026 outlook on prior authorization reform and the Medicare Prescription Payment Plan. Pharmaceutical Commerce continues its H1 Review/H2 ...

Claims target comparative ads that juxtapose tirzepatide’s maximum tolerated doses with semaglutide regimens that omit FDA-approved higher strengths, potentially creating a misleading efficacy ...